Nurix Therapeutics announced updated clinical data from the Company’s ongoing NX-5948-301 Phase 1a/b clinical trial evaluating bexobrutideg (NX-5948), an investigational oral CNS-penetrant BTK degrader, in patients with chronic… read more.
As cases of a deadly cattle disease rise in Arkansas, researchers with the Arkansas Agricultural Experiment Station are testing two treatments they hope will help ranchers protect their… read more.
Using a massage gun on or around the eyes risks major tearing and bruising to the retina—the light sensitive tissue at the back of the eye—doctors warn in… read more.
Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that the ConfIdeS Phase 3 abstract titled “Superior 1-year eGFR Among Highly Sensitized Patients Desensitized with Imlifidase Compared to… read more.
Long-term survival modeling of Boehringer Ingelheim’s oral preferential PDE4B inhibitor, nerandomilast, predicts the therapy could extend survival by up to 5.4 years in adults with idiopathic pulmonary fibrosis… read more.
A new study suggests anesthesiologists may be able to safely increase the likelihood that patients dream during surgery — and that those dreams are typically positive, calming and… read more.
Patients are less likely to become long-term benzodiazepine users when they are initially prescribed shorter courses, a single medication, or short-acting agents, according to a large new study… read more.
Lundbeck A/S today announced that new migraine clinical data will be presented at the European Academy of Neurology (EAN) Congress 2026, taking place 27–30 June in Geneva, Switzerland…. read more.
Pfizer Inc. announced that the FDA has approved an expanded indication for Hympavzi (marstacimab-hncq) to include the treatment of patients with hemophilia A or B 12 years and… read more.
Cognitive behavioural therapies for insomnia (CBT-I) are increasingly being delivered online in order to improve accessibility. However, although insomnia and anxiety frequently occur together in older adults, few… read more.
Sunscreen is overwhelmingly promoted in popular TikTok videos, but content containing health misinformation about sunscreen attracts disproportionately high audience engagement, according to a new study published June 18th in… read more.
Outlook Therapeutics announced the FDA has acknowledged receipt of the resubmission of the Biologics License Application (BLA) for ONS-5010/LYTENAVA for the treatment of neovascular age-related macular degeneration (nAMD),… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
